- Home
- BETR vs HRTX Comparison
BETR vs HRTX Comparison
Compare BETR & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BETR
- HRTX
- Stock Information
- Founded
- BETR 2014
- HRTX 1983
- Country
- BETR United States
- HRTX United States
- Employees
- BETR N/A
- HRTX N/A
- Industry
- BETR Finance: Consumer Services
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- BETR Finance
- HRTX Health Care
- Exchange
- BETR Nasdaq
- HRTX Nasdaq
- Market Cap
- BETR 203.4M
- HRTX 206.9M
- IPO Year
- BETR N/A
- HRTX 1987
- Fundamental
- Price
- BETR $25.55
- HRTX $1.24
- Analyst Decision
- BETR
- HRTX Strong Buy
- Analyst Count
- BETR 0
- HRTX 2
- Target Price
- BETR N/A
- HRTX $4.50
- AVG Volume (30 Days)
- BETR 71.8K
- HRTX 1.4M
- Earning Date
- BETR 11-12-2025
- HRTX 11-11-2025
- Dividend Yield
- BETR N/A
- HRTX N/A
- EPS Growth
- BETR N/A
- HRTX N/A
- EPS
- BETR N/A
- HRTX N/A
- Revenue
- BETR $130,672,000.00
- HRTX $149,694,000.00
- Revenue This Year
- BETR $55.38
- HRTX $10.62
- Revenue Next Year
- BETR $71.18
- HRTX $12.99
- P/E Ratio
- BETR N/A
- HRTX N/A
- Revenue Growth
- BETR 69.42
- HRTX 9.78
- 52 Week Low
- BETR $7.71
- HRTX $1.04
- 52 Week High
- BETR $27.29
- HRTX $2.68
- Technical
- Relative Strength Index (RSI)
- BETR 55.70
- HRTX 30.45
- Support Level
- BETR N/A
- HRTX $1.25
- Resistance Level
- BETR $25.37
- HRTX $1.35
- Average True Range (ATR)
- BETR 1.34
- HRTX 0.06
- MACD
- BETR -0.81
- HRTX 0.01
- Stochastic Oscillator
- BETR 93.62
- HRTX 5.00
About BETR Better Home & Finance Holding Company
Better Home & Finance Holding Co is a digital-first homeownership company whose services include mortgage, real estate, title, and homeowners insurance. The company has combined technology innovation and fresh thinking with a deep customer focus with the goal of revolutionizing the homeownership industry.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.